SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
CSTL Stock | USD 26.83 0.27 1.00% |
About 67% of Castle Biosciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Castle Biosciences suggests that many traders are alarmed. Castle Biosciences' investing sentiment shows overall attitude of investors towards Castle Biosciences.
Castle |
The phase III EMERGENE study evaluates Sareptas experimental gene therapy for an ultra-rare form of muscle disorder for which there is no treatment beyond symptom management.
Read at zacks.com
Castle Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Castle Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Castle Biosciences Fundamental Analysis
We analyze Castle Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Castle Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Castle Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Castle Biosciences is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Castle Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Castle Biosciences stock to make a market-neutral strategy. Peer analysis of Castle Biosciences could also be used in its relative valuation, which is a method of valuing Castle Biosciences by comparing valuation metrics with similar companies.
Peers
Castle Biosciences Related Equities
STIM | Neuronetics | 4.23 | ||||
ENZ | Enzo Biochem | 2.82 | ||||
BNR | Burning Rock | 1.42 | ||||
BDSX | Biodesix | 1.37 | ||||
NTRA | Natera | 0.39 | ||||
SERA | Sera Prognostics | 1.23 | ||||
CDNA | Caredx | 1.63 | ||||
TWST | Twist Bioscience | 2.15 | ||||
FONR | Fonar | 2.29 | ||||
GH | Guardant Health | 2.96 | ||||
PSNL | Personalis | 6.23 | ||||
XGN | Exagen | 6.55 |
Check out Castle Biosciences Hype Analysis, Castle Biosciences Correlation and Castle Biosciences Performance. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share 0.21 | Revenue Per Share 11.34 | Quarterly Revenue Growth 0.395 | Return On Assets (0) |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.